Scarica l'app Stockscreener
7.77
8.07%
0.58
Dopo l'orario di chiusura:
7.55
-0.22
-2.83%
Precedente Chiudi:
$7.19
Aprire:
$7.29
Volume 24 ore:
980.78K
Relative Volume:
1.01
Capitalizzazione di mercato:
$443.94M
Reddito:
$20.72M
Utile/perdita netta:
$-100.84M
Rapporto P/E:
-2.9211
EPS:
-2.66
Flusso di cassa netto:
$-78.56M
1 W Prestazione:
+3.60%
1M Prestazione:
-27.38%
6M Prestazione:
+96.71%
1 anno Prestazione:
+22.17%
Intervallo 1D:
$7.22
$8.06
Intervallo di 1 settimana:
$6.96
$8.06
Portata 52W:
$2.235
$12.34
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Nome
4 D Molecular Therapeutics Inc
Settore
Industria
Telefono
(510) 505-2680
Indirizzo
5858 HORTON STREET #455, EMERYVILLE
Confronta FDMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
7.77 | 410.80M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-07 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Iniziato | Morgan Stanley | Underweight |
| 2024-09-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Iniziato | Barclays | Overweight |
| 2024-02-07 | Ripresa | Goldman | Buy |
| 2023-10-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Iniziato | Chardan Capital Markets | Buy |
| 2023-01-30 | Iniziato | BMO Capital Markets | Outperform |
| 2022-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2022-11-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-12 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Iniziato | Jefferies | Buy |
| 2022-01-04 | Iniziato | SVB Leerink | Outperform |
| 2021-01-05 | Iniziato | BofA Securities | Buy |
| 2021-01-05 | Iniziato | Evercore ISI | Outperform |
| 2021-01-05 | Iniziato | Goldman | Neutral |
Mostra tutto
4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie
4D Molecular Therapeutics, Inc. Announces Executive Changes - MarketScreener
4DMT Provides Company Update and Anticipated Development Milestones for 2026 - The Manila Times
2026 world cup analysis rankings: Will 4D Molecular Therapeutics Inc. stock gain from strong economy2026 world cup usa national team round of 32 defensive leaders counter attacking winner prediction expert opinion - ulpravda.ru
Certain Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - marketscreener.com
Certain Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - MarketScreener
4D Molecular falls after early-stage trial data for cystic fibrosis therapy - MSN
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely - Finviz
Ashoo Gupta of 4D Molecular Therapeutics sells $3.3k in FDMT stock - Investing.com Australia
4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) institutional investors lost 20% over the past week but have profited from longer-term gains - Yahoo Finance
4D Molecular Therapeutics Gains Momentum from Clinical Data and Index Inclusion - AD HOC NEWS
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to S&P Biotechnology Select Industry Index - marketscreener.com
How interest rate cuts could boost 4D Molecular Therapeutics Inc. stockJuly 2025 Chart Watch & Accurate Buy Signal Notifications - Улправда
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Is 4D Molecular Therapeutics Inc. stock ready for breakoutJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - Улправда
4D Molecular Therapeutics Executive Sells Shares - TradingView — Track All Markets
4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT) - Seeking Alpha
Can 4D Molecular Therapeutics Inc. stock double in next 5 yearsJuly 2025 Intraday Action & Weekly High Return Stock Forecasts - DonanımHaber
Is 4D Molecular Therapeutics Inc. stock a top momentum playJuly 2025 Action & Long Hold Capital Preservation Tips - DonanımHaber
Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), 4D Molecular Therapeutics (FDMT) - The Globe and Mail
What insider trading reveals about 4D Molecular Therapeutics Inc. stockQuarterly Portfolio Report & AI Powered Trade Plan Recommendations - DonanımHaber
Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Novan (NOVN) - The Globe and Mail
Stock Market Recap: Is 4D Molecular Therapeutics Inc. stock a top momentum playQuarterly Portfolio Report & Accurate Buy Signal Notifications - DonanımHaber
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Buy” Rating at Chardan Capital - Defense World
Chardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation - Nasdaq
What dividend safety score for 4D Molecular Therapeutics Inc. stockJuly 2025 Action & Long-Term Investment Growth Plans - Улправда
4D Molecular Therapeutics : 710 AEROW Interim Phase 1 Data & Program Update (610855) - marketscreener.com
4D Molecular posts Phase 1 trial data for cystic fibrosis drug - Seeking Alpha
4D Molecular Therapeutics Announces Positive Interim Clinical Data from 4D-710 Aerow Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - marketscreener.com
4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform PotentialSlideshow (NASDAQ:FDMT) 2025-12-17 - Seeking Alpha
4D Molecular Therapeutics Reports Positive Interim Phase 1 Data For 4D-710 In Cystic Fibrosis - Nasdaq
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - Yahoo Finance
Officer Bizily Files To Sell 1,635 Of 4D Molecular Therapeutics Inc [FDMT] - TradingView — Track All Markets
4D Molecular Therapeutics (FDMT) director reports 9,333-share option exercise - Stock Titan
4DMT Announces New Employment Inducement Grants - Sahm
4D Molecular Therapeutics (Nasdaq: FDMT) Issues 13,800 RSUs Under 2025 Inducement Plan - Stock Titan
4D Molecular Therapeutics expands phase 3 trial enrollment - MSN
4D Molecular Therapeutics grants CFO option on 480,000 FDMT shares | FDMT SEC FilingForm 4 - Stock Titan
4D Molecular Therapeutics (FDMT) CFO reports no securities holdings - Stock Titan
4D Molecular Therapeutics Expands Phase 3 Trial Enrollment - TipRanks
4D Molecular Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update - MSN
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Decheng Capital LLC - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 7.4%Here's What Happened - MarketBeat
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN
4D Molecular Therapeutics Reports Strategic Gains in Q3 2025 - MSN
4D Molecular Therapeutics taps Kristian Humer as CFO - MSN
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
4D Molecular Therapeutics Appoints New Financial Officer - MSN
Transcript : 4D Molecular Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 09 - marketscreener.com
FDMT SEC Filings4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
4 D Molecular Therapeutics Inc Azioni (FDMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):